Bioniche Life Sciences Inc. 25 Years
Contact Us Careers
Home Newsroom
In the News

December 1, 2014
Telesta Therapeutics Announces Key Clinical & Corporate Updates

November 25, 2014
BIONICHE LIFE SCIENCES INC. REBRANDS AS TELESTA THERAPEUTICS INC.

Investors

Latest TSX stock price

All prices delayed at least 15 minutes.
Source: TSX Inc.


Newsroom

 

Bioniche Life Sciences Inc. is a leading clinical stage biotechnology company focused on the development, manufacturing, and commercialization of proprietary and innovative therapeutics for the global human health market. The Company’s anchor product is in Phase III clinical development to treat non-muscle-invasive bladder cancer.

The Company is publicly traded on the Toronto Stock Exchange (TSX: BNC).

The information contained in the Company’s news releases was accurate at the time of posting on this website, but the information may be superseded by subsequent corporate disclosures.

News Releases

To receive our news releases directly, please enter your e-mail address here.

Media Coverage

For recent media coverage of Bioniche Life Sciences Inc. click here >>

Latest News

December 1, 2014
Telesta Therapeutics Announces Key Clinical & Corporate Updates more...

November 25, 2014
BIONICHE LIFE SCIENCES INC. REBRANDS AS TELESTA THERAPEUTICS INC. more...

November 13, 2014
Bioniche Life Sciences Inc. Announces Results of Annual General Meeting of Shareholders SHAREHOLDERS more...

More News

Category: 


Bioniche Key Facts

CEO:
Dr. Michael Berendt

TSX stock symbol:
TSX

Fiscal year-end:
June 30

Headquarters:
Belleville, Ontario

Employees:
50

Focus area:
Human Therapeutics

Copyright 2004, Bioniche Life Sciences Inc. All rights reserved  |  Legal Disclaimer  |  Privacy Policy